WO2006086865A3 - Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee - Google Patents

Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee Download PDF

Info

Publication number
WO2006086865A3
WO2006086865A3 PCT/BR2006/000031 BR2006000031W WO2006086865A3 WO 2006086865 A3 WO2006086865 A3 WO 2006086865A3 BR 2006000031 W BR2006000031 W BR 2006000031W WO 2006086865 A3 WO2006086865 A3 WO 2006086865A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
treatment
combi
preparation
reverse transcriptase
Prior art date
Application number
PCT/BR2006/000031
Other languages
English (en)
Other versions
WO2006086865A2 (fr
Inventor
Maira Merces Barreto
Grace Gondin Rei Mafra
Original Assignee
Fundacao Oswaldo Cruz
Maira Merces Barreto
Grace Gondin Rei Mafra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz, Maira Merces Barreto, Grace Gondin Rei Mafra filed Critical Fundacao Oswaldo Cruz
Publication of WO2006086865A2 publication Critical patent/WO2006086865A2/fr
Publication of WO2006086865A3 publication Critical patent/WO2006086865A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui combine des principes actifs antirétroviraux en un seul cachet revêtu. Cette invention concerne aussi un processus de préparation de cette composition, l'utilisation de cette composition dans le traitement de l'immunodéficience humaine causée par une infection par le VIH et un procédé de traitement de l'immunodéficience humaine.
PCT/BR2006/000031 2005-02-21 2006-02-21 Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee WO2006086865A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0500586-8 2005-02-21
BRPI0500586-8A BRPI0500586A (pt) 2005-02-21 2005-02-21 composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento

Publications (2)

Publication Number Publication Date
WO2006086865A2 WO2006086865A2 (fr) 2006-08-24
WO2006086865A3 true WO2006086865A3 (fr) 2006-12-28

Family

ID=36916809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2006/000031 WO2006086865A2 (fr) 2005-02-21 2006-02-21 Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee

Country Status (3)

Country Link
BR (1) BRPI0500586A (fr)
RU (1) RU2007144541A (fr)
WO (1) WO2006086865A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200110500B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
US20020098242A1 (en) * 1997-07-31 2002-07-25 Darder Carlos Picornell Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
WO2004002498A1 (fr) * 2002-06-27 2004-01-08 Glaxo Group Limited Regimes antiviraux
WO2006001029A2 (fr) * 2004-06-25 2006-01-05 Hetero Drugs Limited Compositions antiretrovirales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098242A1 (en) * 1997-07-31 2002-07-25 Darder Carlos Picornell Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
ZA200110500B (en) * 2001-05-11 2002-04-03 Cipla Medpro Pty Ltd Pharmaceutical composition.
WO2004002498A1 (fr) * 2002-06-27 2004-01-08 Glaxo Group Limited Regimes antiviraux
WO2006001029A2 (fr) * 2004-06-25 2006-01-05 Hetero Drugs Limited Compositions antiretrovirales

Also Published As

Publication number Publication date
RU2007144541A (ru) 2009-06-20
WO2006086865A2 (fr) 2006-08-24
BRPI0500586A (pt) 2006-10-10

Similar Documents

Publication Publication Date Title
MX2009013349A (es) Compuestos quimicos.
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
WO2009055006A8 (fr) Darunavir deutéré
WO2007068934A3 (fr) Combinaison pharmaceutique
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2007013047A3 (fr) Compositions pharmaceutiques anti-retrovirales dispersibles dans l'eau
NO20070762L (no) Topiske antivirale preparater
HK1093746A1 (en) Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2006122003A3 (fr) Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih
WO2012039596A3 (fr) Compositions pharmaceutiques pour calanolides, leurs dérivés et analogues, et procédé de production associé
WO2008118849A3 (fr) Inhibiteurs de la protéase du vih-1
CO2021007648A2 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
ZA200706306B (en) Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
WO2009062576A3 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
WO2009126293A3 (fr) Puissants inhibiteurs bifonctionnels nrti-nnrti chimériques de la transcriptase inverse du vih-1
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
WO2006086865A3 (fr) Composition pharmaceutique, processus de preparation de cette composition, utilisation de cette composition dans le traitement de l'immunodeficience causee par une infection par le vih et technique de traitement associee
WO2007042571A8 (fr) Nouveaux derives de pyrimidine-2,4-diamine et leur utilisation comme modulateurs de canaux a potassium actives par calcium a conductance faible
WO2008118879A3 (fr) Composés et compositions antivirales

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A200711687

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2007144541

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 06721591

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6721591

Country of ref document: EP